România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

mallinckrodt medical b.v. - olanda - tc 99 m - acid pentetic - kit pentru produs radiofarmaceutic - 20,8mg - aparat renal compusi cu technetium tc99

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

mallinckrodt medical bv. - olanda - tc 99 m - acid succinic dirmercopto - kit pt. preparat radiofarmaceutic - 1,2mg - aparat renal compusi cu technetium tc99

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

mallinckrodt medical b.v. - olanda - tc 99m - acid pentetic - trusa (kit) pt. preparate radiofarmaceutice - 20,8mg - aparat renal compusi cu technetium tc99

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

curium netherlands b.v. - olanda - tc 99m - acid dirmercopto succinic - kit pt. preparat radiofarmaceutic - 1,2mg - aparat renal compusi cu technetium tc99

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sc balkan pharmaceuticals srl - vincaminum - soluţie injectabilă - 7,5 mg/ml

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

biofarm s.a. - romania - vincaminum - draj. - 10mg - vasodilatatoare periferice alte vasodilatatoare periferice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

laboratorios normon s.a. - spania - mepivacainum - sol. inj. - 30mg/ml - anestezice locale amide

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sc balkan pharmaceuticals srl - vincaminum - soluţie injectabilă - 7,5 mg/ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

biofarm sa, sc - vincaminum - drajeuri - 10 mg

Uniunea Europeană - română - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - fibroză chistică - alte produse ale sistemului respirator - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.